GLP-1 Market
LLY $1382.75 ▼ -2.3% NVO $39.43 ▼ -3.1% PFE $28.06 ▼ -1.4% VKTX $26.17 ▼ -2.6% KLRA $11.79 ▼ -3.4% GPCR $17.36 ▼ -4.5% RHHBY $59.52 ▼ -1.2%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Larazotide Acetate

Company
Interlude Biopharma Co.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 19, 2026

Find a Clinical Trial Near Me

See recruiting studies for Larazotide Acetate and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06904261

    A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

    Not yet reported Amicus Therapeutics 8 participants Est. completion 2028-12 12 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00214500

    A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

    Not yet reported Amicus Therapeutics 9 participants Est. completion 2008-01-29 5 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00283933

    A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

    Not yet reported Amicus Therapeutics 5 participants Est. completion 2008-03-12 2 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00283959

    A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

    Not yet reported Amicus Therapeutics 4 participants Est. completion 2008-05-08 2 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00304512

    A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

    Not yet reported Amicus Therapeutics 9 participants Est. completion 2008-05-09 6 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00362856

    Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

    Not yet reported 9 Meters Biopharma, Inc. 80 participants Est. completion 2007-03-06 9 sites
    Other conditions: Celiac Disease
    View official trial listing →
  • Completed NCT NCT00386165

    Safety Study of Larazotide Acetate to Treat Celiac Disease.

    Not yet reported 9 Meters Biopharma, Inc. 21 participants Est. completion 2006-01-26 1 site Stand-alone
    Other conditions: Celiac Disease
    View official trial listing →
  • Completed NCT NCT00386490

    Safety of Larazotide Acetate in Healthy Volunteers

    Not yet reported 9 Meters Biopharma, Inc. 24 participants Est. completion 2006-02-27 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00492960

    Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

    Not yet reported 9 Meters Biopharma, Inc. 171 participants Est. completion 2009-03 23 sites Stand-alone
    Other conditions: Celiac Disease
    View official trial listing →
  • Terminated NCT NCT00526071

    Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

    Not yet reported Amicus Therapeutics 23 participants Est. completion 2012-09-08 8 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT00620451

    Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

    Not yet reported 9 Meters Biopharma, Inc. 105 participants Est. completion 2009-12 33 sites Stand-alone
    Other conditions: Celiac Disease
    View official trial listing →
  • Completed NCT NCT00889473

    Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

    Not yet reported 9 Meters Biopharma, Inc. 42 participants Est. completion 2010-04 15 sites Stand-alone
    Other conditions: Celiac Disease
    View official trial listing →
  • Completed NCT NCT00925301

    Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

    Not yet reported Amicus Therapeutics 67 participants Est. completion 2014-01-29 28 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01196871

    Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

    Not yet reported Amicus Therapeutics 20 participants Est. completion 2012-10-09 10 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01218659

    Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

    Not yet reported Amicus Therapeutics 68 participants Est. completion 2015-05-28 25 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01396213

    A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

    Not yet reported 9 Meters Biopharma, Inc. 342 participants Est. completion 2013-08-20 62 sites Stand-alone
    Other conditions: Celiac Disease
    View official trial listing →
  • Terminated NCT NCT01458119

    Open-Label Phase 3 Long-Term Safety Study of Migalastat

    Not yet reported Amicus Therapeutics 85 participants Est. completion 2016-02-17 25 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Available NCT NCT01476163

    Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

    Amicus Therapeutics
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01730469

    Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

    Not yet reported Amicus Therapeutics 32 participants Est. completion 2012-04 4 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01730482

    A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

    Not yet reported Amicus Therapeutics 6 participants Est. completion 2011-09
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT01853852

    A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

    Not yet reported Amicus Therapeutics 14 participants Est. completion 2011-12 1 site
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT02082327

    A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers

    Not yet reported Amicus Therapeutics 31 participants Est. completion 2014-06 1 site
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT02194985

    Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

    Not yet reported Amicus Therapeutics 84 participants Est. completion 2019-10-23 28 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT03500094

    Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

    Not yet reported Amicus Therapeutics 22 participants Est. completion 2021-02-06 8 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Terminated NCT NCT03569007

    Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

    Not yet reported 9 Meters Biopharma, Inc. 307 participants Est. completion 2022-07-21 160 sites
    Other conditions: Celiac Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04020055

    A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

    Not yet reported Amicus Therapeutics 14 participants Est. completion 2026-12-31 12 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Completed NCT NCT04049760

    Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

    Not yet reported Amicus Therapeutics 16 participants Est. completion 2024-11-29 6 sites
    Other conditions: Fabry Disease
    View official trial listing →
  • Terminated NCT NCT05022303

    AT1001 for the Treatment of COVID-19 Related MIS-C

    Not yet reported Massachusetts General Hospital 12 participants Est. completion 2024-05-15 1 site Stand-alone
    Other conditions: Covid19, Multisystem Inflammatory Syndrome in Children
    View official trial listing →
  • Completed NCT NCT05747534

    AT1001 for the Treatment of Long COVID

    Not yet reported Massachusetts General Hospital 107 participants Est. completion 2026-06-18 1 site Stand-alone
    Other conditions: Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
    View official trial listing →
  • Not yet recruiting NCT NCT07944625

    Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease

    Not yet reported Interlude Biopharma Co. 414 participants Est. completion 2028-09 Stand-alone
    Other conditions: Celiac Disease, Celiac Disease in Adolescents
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.